Photodynamic Therapy-Current Limitations and Novel Approaches
Gurcan Gunaydin1, M Emre Gedik1, Seylan Ayan2
1Department of Basic Oncology, Hacettepe University Cancer Institute, Sihhiye, Ankara, Turkey.
Abstract:
Photodynamic therapy (PDT) mostly relies on the generation of singlet oxygen, via the excitation of a photosensitizer, so that target tumor cells can be destroyed. PDT can be applied in the settings of several malignant diseases. In fact, the earliest preclinical applications date back to 1900's. Dougherty reported the treatment of skin tumors by PDT in 1978. Several further studies around 1980 demonstrated the effectiveness of PDT. Thus, the technique has attracted the attention of numerous researchers since then. Hematoporphyrin derivative received the FDA approval as a clinical application of PDT in 1995. We have indeed witnessed a considerable progress in the field over the last century. Given the fact that PDT has a favorable adverse event profile and can enhance anti-tumor immune responses as well as demonstrating minimally invasive characteristics, it is disappointing that PDT is not broadly utilized in the clinical setting for the treatment of malignant and/or non-malignant diseases. Several issues still hinder the development of PDT, such as those related with light, tissue oxygenation and inherent properties of the photosensitizers. Various photosensitizers have been designed/synthesized in order to overcome the limitations. In this Review, we provide a general overview of the mechanisms of action in terms of PDT in cancer, including the effects on immune system and vasculature as well as mechanisms related with tumor cell destruction. We will also briefly mention the application of PDT for non-malignant diseases. The current limitations of PDT utilization in cancer will be reviewed, since identifying problems associated with design/synthesis of photosensitizers as well as application of light and tissue oxygenation might pave the way for more effective PDT approaches. Furthermore, novel promising approaches to improve outcome in PDT such as selectivity, bioengineering, subcellular/organelle targeting, etc. will also be discussed in detail, since the potential of pioneering and exceptional approaches that aim to overcome the limitations and reveal the full potential of PDT in terms of clinical translation are undoubtedly exciting. A better understanding of novel concepts in the field (e.g. enhanced, two-stage, fractional PDT) will most likely prove to be very useful for pursuing and improving effective PDT strategies.
Insights
Photodynamic therapy (PDT) destroys tumor cells using light-activated photosensitizers. Despite its potential, PDT is underutilized due to challenges with light, oxygen, and photosensitizer properties, hindering broader clinical application.
Area of Science:
- Oncology
- Photochemistry
- Immunology
Background:
- Photodynamic therapy (PDT) utilizes photosensitizers and light to generate singlet oxygen, leading to targeted tumor cell destruction.
- PDT has a history of preclinical and clinical applications since the late 1970s, with FDA approval for certain uses in 1995.
- Despite its minimally invasive nature and potential to enhance anti-tumor immunity, PDT's clinical use remains limited.
Purpose of the Study:
- To review the mechanisms of photodynamic therapy in cancer treatment, including its effects on the immune system, vasculature, and direct tumor cell killing.
- To discuss the applications of PDT in non-malignant diseases.
- To identify current limitations hindering PDT's broader clinical adoption and explore novel strategies for improvement.
Main Methods:
- Review of existing literature on photodynamic therapy mechanisms, applications, and limitations.
- Analysis of challenges related to light delivery, tissue oxygenation, and photosensitizer properties.
- Exploration of emerging approaches such as enhanced selectivity, bioengineering, and subcellular targeting.
Main Results:
- PDT mechanisms involve singlet oxygen generation, immune system modulation, vascular disruption, and direct tumor cell death.
- Current limitations include issues with light penetration, tumor oxygenation, and photosensitizer characteristics.
- Novel strategies like enhanced PDT, two-stage PDT, and fractional PDT show promise for improving treatment outcomes.
Conclusions:
- Addressing the limitations in light, oxygenation, and photosensitizer design is crucial for advancing PDT.
- Innovative approaches in selectivity, bioengineering, and targeted delivery can enhance PDT's efficacy and clinical translation.
- Further understanding and application of novel PDT concepts are essential for realizing its full therapeutic potential in oncology and beyond.
Related Concept Videos
Confocal Fluorescence Microscopy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...


